Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Portfolio Pulse from
Bolt Biotherapeutics will present data from its Phase 1 clinical study of BDC-3042, a novel immunotherapy targeting dectin-2 in advanced cancer patients, at the AACR Annual Meeting in April 2025. The company will also share preclinical data on two pipeline programs using its Boltbody ISAC platform targeting CEA and PD-L1.
March 25, 2025 | 8:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Presentation of Phase 1 clinical data and preclinical research could provide insights into the company's therapeutic potential and pipeline progress.
Positive research presentations at a major conference like AACR can generate investor interest and potentially boost stock performance, especially for a clinical-stage biotech company.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100